Mandragora

'''Mandrake''' (''Mandragora officinarum'' L., Solanaceae) is a perennial Mediterranean plant whose roots, leaves, and berries produce [[substance_class:chemical/tropane]] alkaloids that classify it as a [[substance_class:psychoactive/deliriant]]. Its principal psychoactive constituent, hyoscyamine, is a competitive [[substance_class:pharmacological/muscarinic-acetylcholine-receptor-antagonist]]. Hyoscyamine produces its effects by blocking central muscarinic signaling, disrupting [[substance_class:chemical/cholinergic]] [[glossary:transmission|neurotransmission]] across cortical and subcortical [[glossary:circuit|circuits]]. Mandrake appears as "dudaim" in the Hebrew Bible and was described by Dioscorides in the 1st century AD as a surgical anesthetic{{cite|doi=10.1186/s13002-019-0338-8|anchor=6ad18648}}{{cite|doi=10.3390/life13091913|anchor=5170dde1}}. It featured in medieval European anesthetic formularies before [[glossary:synthetic]] anticholinergics displaced it from clinical use{{cite|doi=10.1007/s13659-022-00357-w|anchor=a5200e3c}}. No clinical trials have been registered for any ''Mandragora'' species, and contemporary [[glossary:recreational-use]] is extremely rare{{cite|doi=10.1371/journal.pone.0247688|anchor=f5356884}}. [[index:effects|Subjective effects]] include disoriented [[effect:delirium]], vivid but fragmented [[glossary:hallucination|hallucinations]], complete [[effect:amnesia]], and inability to distinguish hallucinated content from reality{{cite|doi=10.1021/acschemneuro.8b00615|anchor=ba5a3119}}. The experience is qualitatively distinct from [[glossary:serotonergic-psychedelics]] — hallucinations are mundane in content, seamlessly integrated into perceived reality, and accompanied by global cognitive disorganization. Characteristic unsought effects include [[glossary:tachycardia]], [[effect:pupil-dilation]], [[glossary:hyperthermia]], [[effect:dry-mouth]], and profound [[effect:dysphoria]]{{cite|doi=10.1371/journal.pone.0247688|anchor=276f724c}}. No [[glossary:physical-dependence]] syndrome has been documented for anticholinergic agents, and compulsive use is unlikely given the characteristically dysphoric experience{{cite|doi=10.1371/journal.pone.0247688|anchor=c5d59bf5}}. ''Mandragora'' preparations carry an extremely narrow margin between perceptible effect and severe anticholinergic [[glossary:toxicity]], with the dominant real-world harm pathway being accidental consumption of berries mistaken for edible plants{{cite|doi=10.1186/1757-1626-2-9331|anchor=68df45b9}}. No controlled human pharmacokinetic data, quantified dose-response relationships, or standardized preparations exist for any ''Mandragora'' species.

'''Mandragora officinarum''' ('''mandrake''') is a perennial plant of the family Solanaceae native to the Mediterranean basin, producing [[substance_class:chemical/tropane]] alkaloids — primarily hyoscyamine and, in some species, [[substance:scopolamine]] — that act as competitive [[substance_class:pharmacological/muscarinic-acetylcholine-receptor-antagonist|muscarinic acetylcholine receptor antagonists]]. The plant is classified as a [[substance_class:psychoactive/deliriant]]; no published dose-characterization data exist for any preparation, and no standardized commercial supply chain has been established. One of the oldest documented medicinal plants in the Western tradition, mandrake appears as "dudaim" in the Hebrew Bible (Genesis 30:14–16) and was formally described by Linnaeus in ''Species Plantarum'' (1753){{cite|doi=10.1186/s13002-019-0338-8|anchor=c5493a4c}}. Dioscorides recorded its use as a surgical anesthetic in the 1st century AD, and tropane alkaloid-containing Solanaceae featured in medieval European anesthetic formularies{{cite|doi=10.3390/life13091913|anchor=205a36f0}}. No clinical trials have been registered for any ''Mandragora'' species, and modern pharmacological characterization is limited to studies of the isolated alkaloids rather than whole-plant preparations. The genus contains three pharmacologically significant species with divergent alkaloid profiles: ''M. officinarum'' produces high levels of hyoscyamine but lacks scopolamine entirely, while ''M. autumnalis'' contains both alkaloids due to a functional hyoscyamine 6β-hydroxylase [[glossary:enzyme]]{{cite|doi=10.1016/j.plantsci.2019.03.013|anchor=947209c7}}. Central muscarinic [[glossary:blockade]] at supratherapeutic doses produces a characteristic deliriant syndrome — disoriented [[effect:delirium]] with vivid but fragmented [[glossary:hallucination|hallucinations]], complete [[effect:amnesia]], and inability to distinguish hallucinated content from reality — qualitatively distinct from [[glossary:serotonergic-psychedelics]]{{cite|doi=10.1021/acschemneuro.8b00615|anchor=3e28d6e6}}. Effects and duration vary substantially by species, plant part, and preparation method. ''Mandragora'' preparations carry an extremely narrow margin between perceptible effect and severe anticholinergic [[glossary:toxicity]]. No safe recreational dose has been established, and the dominant real-world harm pathway is accidental consumption of berries or leaves mistaken for edible plants such as borage{{cite|doi=10.1186/1757-1626-2-9331|anchor=c63bee6e}}. Clinical poisoning produces [[glossary:tachycardia]] (documented at 170–190 bpm), [[effect:pupil-dilation]], [[glossary:hyperthermia]], and delirium; physostigmine is the specific antidote. No [[glossary:physical-dependence]] syndrome has been documented for anticholinergic agents, and compulsive use is unlikely given the characteristically dysphoric experience{{cite|doi=10.1371/journal.pone.0247688|anchor=5e297535}}. Controlled toxicity data, human [[glossary:pharmacokinetics]] for whole-plant preparations, and quantified dose-response relationships for any ''Mandragora'' preparation remain absent from the published literature.

'''Mandrake''' (''Mandragora officinarum'' L., Solanaceae) is a Mediterranean perennial classified as a [[substance_class:psychoactive/deliriant]]. Its primary psychoactive constituent, hyoscyamine, is structurally and mechanistically distinct from [[glossary:serotonergic-psychedelics]]. It blocks [[glossary:acetylcholine]] signaling throughout the brain and body — disrupting [[glossary:perception]], memory, and physiological regulation. Mandrake appears as "dudaim" in the Hebrew Bible and was described by Dioscorides in the 1st century AD as a surgical anesthetic{{cite|doi=10.1186/s13002-019-0338-8|anchor=2ad50d81}}{{cite|doi=10.3390/life13091913|anchor=1fd7da25}}. It featured in medieval European anesthetic preparations — combined with henbane and opium — before [[glossary:synthetic]] anticholinergics displaced it from clinical use{{cite|doi=10.1007/s13659-022-00357-w|anchor=59389382}}. Today it has no approved clinical role, no standardized preparations, and [[glossary:recreational-use]] is extremely rare{{cite|doi=10.1371/journal.pone.0247688|anchor=e58d6f7c}}. [[index:effects|Subjective effects]] include disoriented [[effect:delirium]], fragmented [[glossary:hallucination|hallucinations]], complete [[effect:amnesia]], [[effect:dry-mouth]], racing heart, and elevated [[glossary:body-temperature]]{{cite|doi=10.1021/acschemneuro.8b00615|anchor=860dd3a4}}{{cite|doi=10.1371/journal.pone.0247688|anchor=a9d573c9}}. Unlike serotonergic psychedelics, the hallucinations are mundane and indistinguishable from reality — conversations with absent people, interactions with objects that don't exist. The experience is consistently described as frightening and dysphoric{{cite|doi=10.1371/journal.pone.0247688|anchor=c3a47717}}. No [[glossary:physical-dependence]] syndrome has been documented for anticholinergic agents, but the margin between a perceptible effect and severe [[glossary:toxicity]] is extremely narrow{{cite|doi=10.1371/journal.pone.0247688|anchor=e8a67ba0}}. The dominant real-world harm is accidental poisoning — berries mistaken for edible plants{{cite|doi=10.1186/1757-1626-2-9331|anchor=c30124b4}}. No controlled pharmacokinetic data, dose-response studies, or standardized preparations exist for any ''Mandragora'' species.

===Traditional and historical use=== ''Mandragora'' is among the earliest documented medicinal plants in the Western and Near Eastern pharmacopoeia, appearing as "dudaim" in the Hebrew Bible (Genesis 30:14–16) in association with fertility{{cite|doi=10.1186/s13002-019-0338-8|anchor=e4f82109}}. A spatiotemporal analysis of 292 vernacular names across 41 languages identified the Near East as the origin of the plant's mythology, with the most common name categories relating to anthropomorphism, supernatural agents, narcotic effects, and aphrodisiac properties{{cite|doi=10.1186/s13002-021-00494-5|anchor=761a8b4e}}. Dioscorides provided the first explicit description of mandrake-induced [[glossary:anesthesia]] in the 1st century AD, recording approximately 1 cyathus (~45 mL) of root decoction boiled in wine and administered orally before surgical procedures. Traditional preparation forms included fresh root juice, root boiled in wine, root bark infusion, and sun-dried fruit. These remain traditional-use accounts without clinical confirmation. ===Medieval European use=== Mandrake featured in the "spongia somnifera" — a medieval surgical tool incorporating narcotic [[glossary:plant-material|plant materials]] (mandrake, henbane, opium) as an inhalation preparation for anesthesia. The 13th-century physician Teodorico Borgognoni is recognized as a forerunner of modern anesthesia for his use of such formularies{{cite|doi=10.3390/life13091913|anchor=81bf403d}}. The plant was also a component of ''unguentum sabbati'' ("witches' ointment") recipes, typically combined with belladonna and henbane in animal fat and applied transdermally. The anticholinergic alkaloids — particularly [[substance:scopolamine]] — are pharmacologically capable of transdermal [[glossary:absorption]], producing intense [[effect:delirium]] and sensory distortions historically interpreted as "flying"{{flag|citation-needed}}. ===Modern era=== Linnaeus formalized the binomial ''Mandragora officinarum'' in ''Species Plantarum'' (1753){{cite|name=powo-mandragora|type=book|author=Royal Botanic Gardens Kew|year=2024|title=Mandragora officinarum — Plants of the World Online|anchor=68e66dca}}, with the authoritative taxonomic revision produced by Ungricht, Knapp, and Press in 1998{{cite|doi=10.5281/zenodo.16433981|anchor=19f6f358}}. Traditional medicinal uses documented across the Mediterranean, North Africa, and Himalayan regions include treatment of [[effect:insomnia]], pain, hemorrhoids, and melancholia{{cite|doi=10.2174/1381612827666210203143445|anchor=95935eb4}}{{cite|doi=10.1093/ecam/nel034|anchor=628b263d}}. Pharmaceutical interest in ''Mandragora'' specifically declined as [[glossary:synthetic]] anticholinergics became available. Both atropine and scopolamine — derived from related Solanaceae — now appear on the WHO List of Essential Medicines{{cite|doi=10.1007/s13659-022-00357-w|anchor=f0c06cd7}}. A survey of [[substance_class:psychoactive/hallucinogen]] users in Slovenia found that knowledge of anticholinergic Solanaceae has been largely lost, attributed to severe [[glossary:toxicity]] and characteristically unpleasant effects{{cite|doi=10.1371/journal.pone.0247688|anchor=316486c8}}.

===Ancient record=== ''Mandragora'' is among the earliest documented medicinal plants in the Western and Near Eastern pharmacopoeia. The plant appears as "dudaim" in the Hebrew Bible (Genesis 30:14–16), where it is associated with fertility and aphrodisiac use — one of only five plants mentioned directly as medicinal in the biblical text{{cite|doi=10.1186/s13002-019-0338-8|anchor=c7189b06}}. The plant featured in medical and ritual contexts across ancient Egypt and Mesopotamia. A spatiotemporal analysis of 292 vernacular names for ''Mandragora'' spp. across 41 languages supports the Near East as the origin of the plant's mythology, with the most common name-categories relating to anthropomorphism (33 names), similarity to other plants (28), supernatural agents (28), narcotic effects (21), and aphrodisiac properties (17){{cite|doi=10.1186/s13002-021-00494-5|anchor=6d048d4e}}. Pedanius Dioscorides (''De Materia Medica'', 1st century AD) provided the first explicit description of mandrake-induced [[glossary:anesthesia]] for surgical intervention, recording a dose of approximately 1 cyathus (~45 mL) of root decoction boiled in wine and reduced to one-third volume, administered orally before procedures. Pliny the Elder documented similar applications. Traditional preparation forms included fresh root juice, root boiled in wine, root bark infusion, and sun-dried fruit. These remain traditional-use accounts without clinical confirmation. ===Medieval European use=== Mandrake featured in the "spongia somnifera" (soporific sponge) — a medieval surgical tool incorporating narcotic [[glossary:plant-material|plant materials]] (mandrake, henbane, opium) as an inhalation or topical preparation for anesthesia. The 13th-century physician Teodorico Borgognoni is identified as a forerunner of modern anesthesia whose formulary included such preparations{{cite|doi=10.3390/life13091913|anchor=9b46286d}}. Among the most documented medieval applications is the inclusion of mandrake in ''unguentum sabbati'' ("witches' ointment") recipes — typically combined with belladonna, henbane (''Hyoscyamus niger''), and sometimes monkshood (''Aconitum''), rendered in animal fat and applied transdermally. The anticholinergic alkaloids (particularly [[substance:scopolamine]] from ''M. autumnalis'' in Mediterranean regions) are pharmacologically capable of transdermal [[glossary:absorption]], producing intense [[effect:delirium]] and sensory distortions historically interpreted as "flying." This pharmacological explanation for witch-trial confession traditions has been proposed and debated by historians{{flag|citation-needed}}. ===Taxonomic history and modern era=== Linnaeus formalized the binomial ''Mandragora officinarum'' L. in ''Species Plantarum'' (1753){{cite|name=powo-mandragora|type=book|author=Royal Botanic Gardens Kew|year=2024|title=Mandragora officinarum — Plants of the World Online|anchor=73f846db}}. The authoritative taxonomic revision of the genus was produced by Ungricht, Knapp, and Press in 1998{{cite|doi=10.5281/zenodo.16433981|anchor=0124d6c1}}. Traditional uses documented across the Mediterranean basin, Europe, North Africa, and Himalayan regions include treatment of [[effect:insomnia]], dysuria, hemorrhoids, rheumatic pain, toothache, melancholia, and [[effect:depression]]{{cite|doi=10.2174/1381612827666210203143445|anchor=f63bfc1d}}. Traditional Arab herbal medicine in the Eastern Mediterranean has also incorporated ''Mandragora'' species{{cite|doi=10.1093/ecam/nel034|anchor=85d5dffa}}. All traditional medicinal applications lack clinical confirmation. Hyoscyamine and scopolamine derived from related Solanaceae species entered clinical use in the 19th century for anesthesia premedication, motion sickness, ophthalmology, and gastrointestinal [[glossary:disorder|disorders]]. Both atropine and scopolamine appear on the WHO List of Essential Medicines{{cite|doi=10.1007/s13659-022-00357-w|anchor=10a96340}}. Pharmaceutical interest in ''Mandragora'' specifically declined as [[glossary:synthetic]] anticholinergics became available; a survey of [[substance_class:psychoactive/hallucinogen]] users in Slovenia found that knowledge of anticholinergic Solanaceae has been largely lost, attributed to their severe [[glossary:toxicity]] and characteristically unpleasant effects{{cite|doi=10.1371/journal.pone.0247688|anchor=233c90f2}}.

===Traditional and historical use=== ''Mandragora'' is one of the earliest documented medicinal plants in the Western pharmacopoeia, appearing as "dudaim" in the Hebrew Bible and described by Dioscorides in the 1st century AD as a surgical anesthetic — root decoction boiled in wine, given before procedures{{cite|doi=10.1186/s13002-019-0338-8|anchor=d1309f11}}{{cite|doi=10.3390/life13091913|anchor=5af4b4f7}}. A linguistic study of 292 vernacular names across 41 languages traced its mythology to the Near East, with name categories relating to anthropomorphism, narcotic effects, and aphrodisiac properties{{cite|doi=10.1186/s13002-021-00494-5|anchor=9ad45dce}}. ===Medieval European use=== Mandrake featured in the "spongia somnifera" — a medieval surgical anesthetic combining mandrake, henbane, and opium. The 13th-century physician Teodorico Borgognoni used such preparations{{cite|doi=10.3390/life13091913|anchor=54574fde}}. It also appeared in "witches' ointment" recipes: mandrake, belladonna, and henbane in animal fat, applied transdermally to produce [[effect:delirium]] historically interpreted as "flying"{{flag|citation-needed}}. ===Modern era=== Pharmaceutical interest declined as [[glossary:synthetic]] anticholinergics became available — atropine and [[substance:scopolamine]] now appear on the WHO List of Essential Medicines{{cite|doi=10.1007/s13659-022-00357-w|anchor=737f2d9a}}. Traditional medicinal uses across the Mediterranean and Himalayas addressed [[effect:insomnia]], pain, and melancholia{{cite|doi=10.2174/1381612827666210203143445|anchor=e9ee6207}}{{cite|doi=10.1093/ecam/nel034|anchor=dd8a6b55}}. A survey of [[substance_class:psychoactive/hallucinogen]] users found knowledge of anticholinergic Solanaceae largely lost, attributed to severe [[glossary:toxicity]] and unpleasant effects{{cite|doi=10.1371/journal.pone.0247688|anchor=c06cf491}}.

The genus ''Mandragora'' comprises three recognized species of pharmacological significance{{cite|doi=10.5281/zenodo.16433981|anchor=bde63e5d}}: * ''M. officinarum'' L. (spring mandrake) — native to northern Italy, the northwestern Balkans, and Lebanon-Syria * ''M. autumnalis'' Bertol. (autumn mandrake) — distributed across the broader Mediterranean basin, including North Africa (Morocco, Algeria) and the Levant * ''M. turcomanica'' Mizgir. (Central Asian mandrake) — Turkmenistan and Afghanistan Accepted synonyms for ''M. officinarum'' include ''Atropa mandragora'' L., ''Atropa humilis'' Salisb., ''Mandragora acaulis'' Gaertn., ''Mandragora neglecta'' G.Don, ''Mandragora praecox'' Sweet, ''Mandragora vernalis'' Bertol., and ''Mandragora officinalis'' Mill. ex DC.{{cite|name=powo-mandragora|type=book|author=Royal Botanic Gardens Kew|year=2024|title=Mandragora officinarum — Plants of the World Online|anchor=4f617280}} ===Morphology=== ''Mandragora'' is acaulescent (stemless), forming a basal rosette of large, wrinkled leaves at ground level. The root is large, fleshy, often branched, and frequently anthropomorphic in shape — a morphological feature that drove centuries of associated mythology. Orange-yellow berries approximately the size of a cherry tomato ripen in spring (''M. officinarum'') or autumn (''M. autumnalis''). ===Misidentification risk=== The berries and leaf rosette of ''Mandragora'' have been mistaken for edible plants, particularly borage (''Borago officinalis'') and other leafy vegetables. Two adults in Crete were hospitalized after consuming ''Mandragora'' berries they had identified as borage{{cite|doi=10.1186/1757-1626-2-9331|anchor=b2adf823}}. In North America, the common name "mandrake" is also applied to ''Podophyllum peltatum'' (American mandrake or mayapple), a taxonomically unrelated plant with entirely different [[glossary:toxicology]] (podophyllotoxin, a [[glossary:cytotoxicity|cytotoxic]] lignan). A clinical case documented a patient who developed severe [[effect:nausea]] and [[effect:vomiting]] after purchasing what was sold as "mandrake" at a health food store; chromatographic analysis identified ''Podophyllum peltatum'' rather than ''Mandragora officinarum''{{cite|pubmed=9308513|anchor=11fc5ccc}}. This name [[effect:confusion]] carries direct clinical safety implications: the two plants require different toxicological management. No established commercial cultivation for pharmaceutical or supplement markets has been documented. Wild-harvested material is not standardized, and alkaloid content varies by species, plant part, developmental stage, and growing conditions.

''Mandragora'' is a genus of perennial herbs in the nightshade family (Solanaceae), closely related to belladonna, henbane, and jimsonweed. Three pharmacologically significant species exist: ''M. officinarum'' (spring mandrake), ''M. autumnalis'' (autumn mandrake), and ''M. turcomanica''. The species matters for the experience — ''M. officinarum'' produces hyoscyamine but no [[substance:scopolamine]], while ''M. autumnalis'' produces both{{cite|doi=10.1016/j.plantsci.2019.03.013|anchor=92817d7e}}. The genus is native to the Mediterranean basin, with populations across southern Europe, North Africa, the Levant, and into Himalayan regions. Plants grow in rocky, calcareous soils at low to moderate [[glossary:elevation|elevations]]. ''Mandragora'' is not commercially cultivated — it is primarily encountered as wild populations or specialty horticultural specimens. The plant grows as a basal rosette of large, wrinkled, dark green leaves with no visible above-ground stem. Flowers are bell-shaped — purple or greenish-white depending on species. The ripe fruit is an orange-yellow berry, roughly 2–3 cm across — easily mistaken for borage or other edible plants, and the most common source of accidental poisoning{{cite|doi=10.1186/1757-1626-2-9331|anchor=f03d934b}}.

''Mandragora'' is a genus of perennial herbaceous plants in the family Solanaceae (nightshades), closely related to ''Atropa belladonna'', ''Hyoscyamus niger'', and ''Datura stramonium''. Three pharmacologically significant species are recognized: ''M. officinarum'' L. (spring mandrake), ''M. autumnalis'' Bertol. (autumn mandrake), and ''M. turcomanica''. Each carries a distinct alkaloid profile with direct consequences for psychoactive character — ''M. officinarum'' produces hyoscyamine but lacks [[substance:scopolamine]] entirely, while ''M. autumnalis'' contains both alkaloids{{cite|doi=10.1016/j.plantsci.2019.03.013|anchor=1899e159}}. The genus is native to the Mediterranean basin, with populations documented across southern Europe, North Africa, the Levant, and extending into Himalayan regions. ''M. officinarum'' and ''M. autumnalis'' co-occur in parts of the Mediterranean but differ in flowering season — spring and autumn respectively. The plants grow in rocky, calcareous soils and disturbed ground at low to moderate [[glossary:elevation|elevations]]. ''Mandragora'' is not widely cultivated commercially and is primarily encountered as wild populations or specialty horticultural specimens. The plant produces a large, fleshy, branching taproot — often forked in a shape historically interpreted as anthropomorphic, which generated extensive mythology. Above ground, it forms a basal rosette of large, wrinkled, dark green leaves. Flowers are bell-shaped, typically purple or greenish-white depending on species. The fruit is an orange-yellow berry when ripe, approximately 2–3 cm in diameter. The berries and leaves are the most common source of accidental poisoning, as they can be mistaken for edible plants such as borage or spinach{{cite|doi=10.1186/1757-1626-2-9331|anchor=cf6b6e3a}}. All parts of the plant contain [[substance_class:chemical/tropane]] alkaloids, with concentrations varying by species, plant part, developmental stage, and growing conditions.

The dominant alkaloids are hyoscyamine and, in certain species, [[substance:scopolamine]] — both [[substance_class:chemical/tropane]] alkaloids that block [[glossary:acetylcholine]] [[glossary:receptor|receptors]] throughout the brain and body{{cite|doi=10.1021/acschemneuro.8b00615|anchor=90baa73b}}{{cite|doi=10.1007/s13659-022-00357-w|anchor=3b35e161}}. Hyoscyamine converts to atropine during drying and extraction, so dried preparations typically contain a mix of both forms. The species determines the alkaloid mix. ''M. officinarum'' produces hyoscyamine but no scopolamine; ''M. autumnalis'' contains both because it carries an [[glossary:enzyme]] that converts hyoscyamine into scopolamine{{cite|doi=10.1016/j.plantsci.2019.03.013|anchor=09438b2d}}. Scopolamine crosses the [[glossary:blood-brain-barrier]] more readily than hyoscyamine, so ''M. autumnalis'' preparations likely produce stronger central effects relative to peripheral symptoms. Alkaloid concentrations vary substantially by species, plant part, developmental stage, and growing conditions. ''Mandragora'' also contains withanolides and coumarins, though whether these modify the tropane alkaloids' effects in whole-plant preparations is unknown. No standardized preparations exist — dose prediction from raw [[glossary:plant-material]] is not possible.

The dominant alkaloids in ''Mandragora'' are [[substance_class:chemical/tropane]] alkaloids — principally hyoscyamine and, in certain species, [[substance:scopolamine]]. These are competitive [[glossary:antagonist|antagonists]] at [[glossary:muscarinic-acetylcholine-receptor|muscarinic acetylcholine receptors]] (M₁–M₅), producing both peripheral and central anticholinergic effects{{cite|doi=10.1021/acschemneuro.8b00615|anchor=fbfe31b1}}{{cite|doi=10.1007/s13659-022-00357-w|anchor=d704ae54}}. Hyoscyamine racemizes to atropine during extraction and drying, so both forms are typically present in preparations made from dried [[glossary:plant-material]]. The species consumed determines the alkaloid composition. ''M. officinarum'' produces high levels of hyoscyamine but lacks scopolamine entirely, while ''M. autumnalis'' contains both alkaloids due to a functional hyoscyamine 6β-hydroxylase [[glossary:enzyme]] that converts hyoscyamine to scopolamine{{cite|doi=10.1016/j.plantsci.2019.03.013|anchor=0f5de2a2}}. This enzymatic difference means the two species produce pharmacologically distinct profiles — ''M. autumnalis'' preparations carry greater [[glossary:central-nervous-system|CNS]]-penetrant alkaloid load because scopolamine crosses the [[glossary:blood-brain-barrier]] more readily than hyoscyamine or atropine. Scopolamine produces more pronounced [[effect:sedation]], [[effect:amnesia]], and [[glossary:hallucination|hallucinations]] at lower doses relative to peripheral effects. Hyoscyamine and atropine produce prominent peripheral anticholinergic effects: [[effect:pupil-dilation]], [[effect:dry-mouth]], [[glossary:tachycardia]], urinary retention, decreased bowel motility, and bronchodilation. Beyond the principal tropane alkaloids, ''Mandragora'' contains non-alkaloid constituents including withanolides and coumarins. Whether these compounds modulate the pharmacological activity of the tropane alkaloids in whole-plant preparations remains unknown — no studies have examined the interaction between tropane alkaloids and the plant's non-alkaloid matrix. Alkaloid concentrations vary substantially by species, plant part, developmental stage, and growing conditions. No analytical data characterizing batch-to-batch variability in wild-harvested material have been published, and no standardized commercial preparations exist. This variability makes dose prediction from raw plant material impossible.

''Mandragora'' species belong to the [[substance_class:chemical/tropane]] alkaloid-producing [[glossary:lineage]] of the Solanaceae{{cite|doi=10.1007/s13659-022-00357-w|anchor=a8b5604b}}{{cite|doi=10.1177/1934578x0800300420|anchor=74c7d09d}}. Over 80 distinct substances have been identified from all parts of the genus{{cite|pubmed=16137728|anchor=f8745e47}}. ===Dominant alkaloids and species-level divergence=== A critical species-level divergence governs the alkaloid profile of ''Mandragora''{{cite|doi=10.1016/j.plantsci.2019.03.013|anchor=dfb30068}}: * ''M. officinarum'' and ''M. turcomanica'' contain '''high levels of hyoscyamine''' but lack anisodamine and [[substance:scopolamine]] entirely. * ''M. autumnalis'' contains '''both hyoscyamine and scopolamine''', with up to 10-fold lower hyoscyamine than ''M. officinarum''. The molecular basis for this divergence is a single G→T mutation at nucleotide 663 of the ''MoH6H'' gene in ''M. officinarum'', which renders hyoscyamine 6β-hydroxylase (H6H) — the [[glossary:enzyme]] that converts hyoscyamine to anisodamine and subsequently to scopolamine — functionally inactive. The ''MaH6H'' gene in ''M. autumnalis'' encodes an active H6H enzyme{{cite|doi=10.1016/j.plantsci.2019.03.013|anchor=b0b5559a}}. This distinction is pharmacologically significant: scopolamine has greater [[glossary:central-nervous-system|CNS]] penetrance than hyoscyamine, producing more pronounced [[effect:sedation]], [[effect:amnesia]], and [[glossary:hallucination|hallucinations]] at lower doses relative to peripheral anticholinergic effects. ===Quantitative data=== Roots of ''M. autumnalis'' at flowering stage contain approximately 0.2% atropine-equivalent alkaloids by capillary gas chromatography{{cite|doi=10.2174/1381612827666210203143445|anchor=116afc34}}. A 2025 HPLC-DAD study comparing four Solanaceae found no detectable hyoscyamine or scopolamine in their ''M. officinarum'' accessions, while ''Atropa belladonna'' yielded hyoscyamine 1,466–5,117 mg/kg dry weight and scopolamine 140–1,743 mg/kg dry weight{{cite|doi=10.1080/14786419.2023.2269595|anchor=d25fc501}}. {{Warning}}This discrepancy likely reflects accession-level, plant-part, or sample-preparation differences rather than a fundamental contradiction of the biochemical evidence confirming hyoscyamine production in ''M. officinarum''. Much historical literature attributes "atropine and scopolamine" to the genus without species-level differentiation. Alkaloid content should not be assumed from genus-level references alone.{{/Warning}} ===Identified alkaloid constituents=== * '''Hyoscyamine''' — dominant in ''M. officinarum'' and ''M. turcomanica'' * '''Scopolamine''' (hyoscine) — present in ''M. autumnalis''; absent in ''M. officinarum'' * '''Atropine''' — [[glossary:racemic-mixture]] of (±)-hyoscyamine; formed during extraction and processing * Cuscohygrine (C₁₃H₂₄N₂O) * Apoatropine * 3α-Tigloyloxytropane * 3α,6β-Ditigloyloxytropane * Belladonnine The compound "mandragorine," commonly cited in older popular literature as a distinctive alkaloid of mandrake, does not appear in PubChem and may represent a historical synonym or [[glossary:misidentification]]{{flag|citation-needed}}. ===Non-alkaloid constituents=== '''Withanolides:''' Mandragorolide A and B were the first withanolides isolated from the genus ''Mandragora'' (Jordanian ''M. officinarum'' origin), alongside larnaxolide A, withanolide B, [[substance:datura]] [[substance_class:chemical/lactone]] 2, withanicandrin, and salpichrolide C{{cite|doi=10.1016/j.fitote.2010.05.013|anchor=6a1a77a2}}. '''Coumarins:''' Five coumarins have been identified from ''M. autumnalis'' roots, leaves, and unripe fruits, including umbelliferone and scopoletin{{cite|doi=10.2174/1381612827666210203143445|anchor=fb790a0f}}. '''Flavonoids:''' Kaempferol, luteolin, myricetin, and (+)-taxifolin have been isolated from ''M. autumnalis'' fruit{{cite|doi=10.3390/molecules27031046|anchor=aee106d9}}.

===Where it acts=== The [[substance_class:chemical/tropane]] alkaloids block [[glossary:acetylcholine]] [[glossary:receptor|receptors]] throughout the brain and peripheral nervous system{{cite|doi=10.1021/acschemneuro.8b00615|anchor=63103c99}}{{cite|doi=10.1007/s13659-022-00357-w|anchor=fa6c74fb}}. No serotonergic or [[glossary:glutamate]] involvement has been documented — the [[glossary:hallucination|hallucinations]] are purely anticholinergic in origin. [[substance:scopolamine]] penetrates the brain more readily than hyoscyamine, which is why ''M. autumnalis'' likely produces stronger central effects. ===What it changes=== High doses produce a '''deliriant syndrome''': disoriented [[effect:delirium]], hallucinations indistinguishable from reality, and dense [[effect:amnesia]]{{cite|doi=10.1021/acschemneuro.8b00615|anchor=9122e0c1}}. There are no geometric visuals and no preserved [[glossary:insight]] — this is nothing like a serotonergic [[substance_class:psychoactive/psychedelic]]. [[glossary:tolerance]] to anticholinergic effects is recognized with repeated pharmaceutical use of scopolamine and atropine, though the mechanism in whole-plant preparations is uncharacterized. {{DiscoverMore|Open Questions}} Key unknowns include: (1) whether the alkaloid ratio differences between ''M. officinarum'' and ''M. autumnalis'' produce qualitatively distinct [[glossary:intoxication]] profiles; (2) the [[glossary:pharmacokinetics]] of transdermal [[glossary:absorption]] from historical ointment preparations; and (3) the interaction between tropane alkaloids and the plant's non-alkaloid constituents (withanolides, coumarins) in whole-plant preparations. {{/DiscoverMore}}

===Where it acts=== The [[substance_class:chemical/tropane]] alkaloids in ''Mandragora'' block [[glossary:muscarinic-acetylcholine-receptor|muscarinic acetylcholine receptors]] (M₁–M₅) throughout the central and peripheral nervous system{{cite|doi=10.1021/acschemneuro.8b00615|anchor=f2aac16f}}{{cite|doi=10.1007/s13659-022-00357-w|anchor=1d08fc45}}. No serotonergic or glutamatergic [[glossary:receptor]] involvement has been documented — the hallucinatory profile is exclusively anticholinergic. [[substance:scopolamine]] crosses the [[glossary:blood-brain-barrier]] more readily than hyoscyamine, which is why ''M. autumnalis'' (containing both alkaloids) likely produces more pronounced central effects relative to peripheral symptoms. ===What it changes=== At supratherapeutic doses, central muscarinic [[glossary:blockade]] produces a '''deliriant syndrome''' — disoriented [[effect:delirium]] with vivid [[glossary:hallucination|hallucinations]], abolished reality testing, and dense [[effect:amnesia]]{{cite|doi=10.1021/acschemneuro.8b00615|anchor=0e3ae4b7}}. This differs fundamentally from serotonergic psychedelia: there are no geometric visuals, no emotional deepening, and no preserved [[glossary:insight]]. The hallucinations are mundane — conversations with absent people, interactions with nonexistent objects — and seamlessly woven into perceived reality. [[glossary:tolerance]] to anticholinergic effects develops with repeated pharmaceutical scopolamine and atropine administration, though the mechanism in whole-plant preparations is uncharacterized. {{DiscoverMore|Open Questions}} Key unknowns include: (1) whether the alkaloid ratio differences between ''M. officinarum'' and ''M. autumnalis'' produce qualitatively distinct [[glossary:intoxication]] profiles; (2) the [[glossary:pharmacokinetics]] of transdermal [[glossary:absorption]] from historical ointment preparations; and (3) the interaction between tropane alkaloids and the plant's non-alkaloid constituents (withanolides, coumarins) in whole-plant preparations. {{/DiscoverMore}}

The defining character of ''Mandragora'' [[glossary:intoxication]] is the abolition of reality testing. Hallucinated content — typically mundane, such as conversations with absent persons or interactions with nonexistent objects — is seamlessly integrated into perceived reality with no [[glossary:awareness]] that the experience is drug-induced. This is accompanied by agitated [[effect:confusion]], dense [[effect:amnesia]], and prominent peripheral effects including [[effect:dry-mouth]], [[glossary:tachycardia]], [[effect:pupil-dilation]], and [[glossary:hyperthermia]]. The species consumed determines the alkaloid mix and likely modulates the ratio of central to peripheral effects, though this has not been empirically compared. ''Mandragora'' intoxication belongs to the same pharmacological [[glossary:class-a|class as]] ''Datura stramonium'' and ''Atropa belladonna'' — anticholinergic Solanaceae whose effects arise from [[glossary:muscarinic-acetylcholine-receptor]] [[glossary:blockade]] rather than [[glossary:monoamine]] or [[substance_class:chemical/indoleamine]] [[glossary:modulation]]. The experience is qualitatively distinct from [[glossary:serotonergic-psychedelics|classical psychedelics]], [[substance_class:psychoactive/dissociative|dissociatives]], and [[substance:cannabis]]: there is no geometric visual patterning, no emotional deepening or mystical [[glossary:phenomenology]], and no preserved [[glossary:insight]] during the episode.

''Mandragora'' [[glossary:intoxication]] abolishes reality testing. Hallucinated content — typically mundane, such as conversations with absent people or interactions with objects that don't exist — is seamlessly woven into perceived reality with no [[glossary:awareness]] that the experience is drug-induced. This is accompanied by agitated [[effect:confusion]], dense [[effect:amnesia]], [[effect:dry-mouth]], racing heart, dilated pupils, and elevated [[glossary:body-temperature]]. ''Mandragora'' belongs to the same pharmacological [[glossary:class-a|class as]] ''Datura'' and belladonna — anticholinergic Solanaceae driven by [[glossary:muscarinic-acetylcholine-receptor]] [[glossary:blockade]] rather than [[glossary:serotonin]] or [[substance_class:psychoactive/dissociative]] mechanisms. The experience is qualitatively unlike [[glossary:serotonergic-psychedelics|classical psychedelics]], dissociatives, or [[substance:cannabis]]: no geometric visuals, no emotional deepening, no preserved [[glossary:insight]] during the episode. The dominant [[glossary:phenomenology]] is confusion and fear, not [[glossary:perception]] altered with awareness intact.

{{Warning}}No published controlled human dose-response studies exist for any ''Mandragora'' preparation. All dose information below derives from historical accounts, clinical [[glossary:toxicology]] [[glossary:case-report|case reports]], or [[glossary:inference|extrapolation]] from pharmaceutical literature on isolated alkaloids. No safe recreational dose has been established for any preparation. Alkaloid content varies by species, plant part, developmental stage, and growing conditions; dose-to-effect relationships cannot be reliably predicted from raw material weight.{{/Warning}} ===Root decoction (oral)=== The historically documented oral preparation is root material boiled in wine and reduced to approximately one-third volume. Dioscorides recorded a dose of approximately 1 cyathus (~45 mL) of this decoction for surgical [[glossary:anesthesia]] (1st century AD){{flag|safety-citation-needed}}. This is traditional-use data only; no controlled pharmacological study of this preparation has been conducted. * '''Onset:''' Estimated 30–60 minutes, consistent with oral anticholinergic [[glossary:pharmacokinetics]] derived from pharmaceutical [[substance:scopolamine]] data{{cite|pubmed=16175141|anchor=ecda909f}} * '''Duration:''' Estimated 4–8+ hours based on anticholinergic kinetics; severe poisoning cases documented persistent supraventricular [[glossary:tachycardia]] for up to 5 days{{cite|doi=10.1186/1757-1626-2-9331|anchor=e043eaa0}} * '''Dose:''' No quantified dose-response data exist. Traditional accounts cite doses as low as 3–6 g of dried root material as potentially fatal{{flag|safety-citation-needed}}; alkaloid variability across plant parts and species makes any fixed dose threshold unreliable. ===Berry (accidental oral ingestion)=== The orange-yellow berries of ''Mandragora'' are the most frequently documented source of accidental poisoning. In clinical case reports, two adults consumed berries mistaken for borage and developed [[effect:nausea]], [[effect:dizziness]], [[effect:visual-acuity-suppression]], [[effect:dry-mouth]], [[effect:headache]], instability in walking, [[effect:vomiting]], flushed skin, reactive [[effect:pupil-dilation]], and supraventricular tachycardia with pulse rates of 190 and 170 bpm{{cite|doi=10.1186/1757-1626-2-9331|anchor=bf2d8c17}}. A separate case documented accidental [[glossary:ingestion]] of berries believed to be aphrodisiac, with analytical toxicology confirmation{{cite|doi=10.1016/j.jemermed.2011.03.023|anchor=b0235c8c}}. The quantity of berries consumed was not specified in either report. No intentional dose-response characterization of berry preparations exists. ===Topical ointment (historical)=== Historical European sources describe ''unguentum sabbati'' preparations combining mandrake with belladonna, henbane, and sometimes monkshood, rendered in animal fat (lard or tallow) and applied to skin — particularly axillary and perineal regions or mucosal surfaces where [[glossary:absorption]] is most efficient. Transdermal absorption of [[substance_class:chemical/tropane]] alkaloids through skin is pharmacologically validated{{cite|doi=10.1021/acs.molpharmaceut.1c00238|anchor=ede07603}}. Commercial transdermal scopolamine patches achieve tmax at approximately 8 hours{{cite|pubmed=16175141|anchor=26790b90}}. Historical ointments were not standardized, and absorption kinetics would have been highly variable. No controlled pharmacological study of historical ointment recipes has been conducted. The claim that these preparations produced hallucinatory experiences is based on historical accounts and pharmacological plausibility, not empirical confirmation{{flag|citation-needed}}. See the Dose by preparation card for structured dose data where available. ===Potency variability=== ''Mandragora'' is exclusively wild-harvested, with no commercial standardization. Alkaloid concentrations differ between species (''M. officinarum'' vs. ''M. autumnalis''), plant parts (root, leaf, fruit, seed), developmental stage, and growing conditions. An HPLC-DAD study found no detectable hyoscyamine or scopolamine in tested ''M. officinarum'' accessions, while the same methodology readily quantified these alkaloids in ''Atropa belladonna'' samples{{cite|doi=10.1080/14786419.2023.2269595|anchor=5891d4f9}}. This underscores the impossibility of predicting alkaloid exposure from material weight alone.

No published dose-characterization data exist for any ''Mandragora'' preparation. No standardized commercial supply chain has been established. All preparations carry an extremely narrow and unpredictable margin between perceptible effect and severe anticholinergic [[glossary:toxicity]]. The following documents historically recorded and real-world exposure forms. '''No safe dose has been established for any form.''' ====Root decoction in wine==== The oldest documented preparation. Dioscorides recorded approximately 1 cyathus (~45 mL) of root decoction boiled in wine and reduced to one-third volume, given orally before surgical procedures{{cite|doi=10.1186/s13002-019-0338-8|anchor=8a099ee2}}. Alkaloid concentration depends entirely on root material, species, and boiling duration. This is a historical account without clinical confirmation — no modern pharmacokinetic data exist for this preparation. ====Topical ointment==== Historical "witches' ointment" preparations combined mandrake with belladonna and henbane in animal fat, applied to the skin. [[substance:scopolamine]] can absorb transdermally — pharmaceutical patches deliver [[glossary:steady-state|steady-state concentrations]] of 56–245 pg/mL over 72 hours{{cite|pubmed=16175141|anchor=496e2b71}}{{cite|doi=10.1021/acs.molpharmaceut.1c00238|anchor=15b8e098}}. Alkaloid delivery from crude plant-fat mixtures cannot be compared to pharmaceutical patch formulations, and no pharmacokinetic data exist for traditional ointment preparations. ====Raw plant material (accidental ingestion)==== The dominant real-world exposure pathway is accidental consumption of berries or leaves mistaken for edible plants such as borage{{cite|doi=10.1186/1757-1626-2-9331|anchor=000437f0}}. Documented cases involved berries consumed as food or believed aphrodisiac{{cite|doi=10.1016/j.jemermed.2011.03.023|anchor=b52518e5}}. The quantity that produces clinical toxicity is unknown and varies by species, plant part, and alkaloid content. ====Oral pharmacokinetics (isolated alkaloids)==== No pharmacokinetic data exist for whole-plant ''Mandragora'' preparations in humans. For pharmaceutical scopolamine taken orally: onset approximately 30 minutes; oral [[glossary:bioavailability]] only 3–27% due to extensive [[glossary:metabolism|liver metabolism]]; both scopolamine and hyoscyamine cross the [[glossary:blood-brain-barrier]] and placenta readily{{cite|pubmed=16175141|anchor=2a24d121}}.

====Toxicity==== No [[glossary:lethal-dose|LD50]] has been established for whole-plant ''Mandragora'' preparations in any species. No controlled [[glossary:toxicity]] data exist. The safety profile derives entirely from clinical [[glossary:case-report|case reports]] and [[glossary:inference|extrapolation]] from pharmaceutical anticholinergic literature. Acute poisoning produces the classic '''anticholinergic toxidrome''': [[glossary:hyperthermia]] from anhidrosis, dry mucous membranes, cutaneous flushing, [[effect:pupil-dilation]] with [[effect:visual-acuity-suppression]], and excited delirium with [[glossary:hallucination|hallucinations]] and [[effect:amnesia]]{{cite|doi=10.1021/acschemneuro.8b00615|anchor=890a921a}}. Two adults in Crete developed supraventricular [[glossary:tachycardia]] (pulse 170–190 bpm), [[effect:nausea]], [[effect:vomiting]], blurred vision, and flushed skin after eating ''Mandragora'' berries mistaken for borage. Tachycardia persisted for 5 days; treatment required physostigmine 1 mg IV daily following gastric lavage. Both recovered fully within 10 days{{cite|doi=10.1186/1757-1626-2-9331|anchor=79fb4653}}. A separate case confirmed poisoning from berries consumed as a believed aphrodisiac via analytical [[glossary:toxicology]]{{cite|doi=10.1016/j.jemermed.2011.03.023|anchor=2b4389e9}}. A fatal [[substance:scopolamine]] case — an inmate who smoked scopolamine tablets — demonstrated [[glossary:fatality|lethality]] at peripheral [[glossary:plasma-concentration|blood concentrations]] of 14 ng/mL, with cerebral and pulmonary edema on pathology{{cite|doi=10.1007/s00414-021-02583-2|anchor=b79e53e1}}. While not a ''Mandragora'' preparation, this establishes that scopolamine at toxic concentrations is directly lethal. ''Mandragora'' is wild-harvested with no standardized commercial preparations, no [[glossary:fda]] or EMA-approved products, and no quality control infrastructure. Key [[glossary:contamination]] and safety vectors include: * '''Misidentification as food plants:''' documented cause of clinical poisoning — berries and leaves mistaken for borage, spinach, or other leafy vegetables{{cite|doi=10.1186/1757-1626-2-9331|anchor=35de3465}} * '''Commercial mislabeling:''' North American products sold as "mandrake" may contain ''Podophyllum peltatum'' (a [[glossary:cytotoxicity|cytotoxic]] lignan source) instead of ''Mandragora officinarum'' — two plants with radically different toxicological profiles{{cite|pubmed=9308513|anchor=77689857}} * '''Batch variability:''' alkaloid concentrations vary by species, plant part, developmental stage, and growing conditions — no standardization is possible from wild material * '''Absence of testing:''' no ISO/IEC-accredited laboratory testing programs, Certificate of Analysis requirements, or regulated supply chain exist for ''Mandragora'' preparations{{flag|citation-needed}} ====Psychological Risks==== The [[substance_class:psychoactive/deliriant]] syndrome is characterized by global cognitive disorganization, agitated [[effect:confusion]], vivid hallucinations indistinguishable from reality, and complete or partial amnesia{{cite|doi=10.1021/acschemneuro.8b00615|anchor=3d6357ff}}. Unlike [[glossary:serotonergic-psychedelics]], reality testing is abolished — the user cannot recognize the hallucinatory nature of the experience during the episode. Severe psychological [[glossary:distress]] during anticholinergic [[effect:delirium]] is the norm rather than the exception. The experience is consistently described as frightening, confusing, and dysphoric{{cite|doi=10.1371/journal.pone.0247688|anchor=ae7133b3}}. No dose titration strategy has been established that reliably produces psychoactive effects without risk of severe toxicity. Persistent psychological sequelae from acute anticholinergic [[glossary:intoxication]] have not been systematically studied. Chronic anticholinergic exposure is associated with cognitive decline and increased dementia risk in pharmacoepidemiological studies, though this literature applies to sustained therapeutic dosing rather than acute plant intoxication{{flag|citation-needed}}. ====Tolerance & Dependence==== No published data on [[glossary:tolerance]], physical dependence, or [[glossary:withdrawal]] exist for ''Mandragora'' preparations specifically. Tolerance to anticholinergic effects is recognized with repeated pharmaceutical scopolamine and atropine administration, but no physical dependence syndrome or characterized withdrawal has been documented for anticholinergic agents as a class. Compulsive use of ''Mandragora'' or related anticholinergic Solanaceae is unlikely. A survey of [[substance_class:psychoactive/hallucinogen]] users found that knowledge of these plants has been largely lost, attributed to severe toxicity and characteristically unpleasant effects{{cite|doi=10.1371/journal.pone.0247688|anchor=8c4e2acb}}. ====Drug Interactions==== Herb-[[glossary:drug-interaction]] data specific to ''Mandragora'' preparations do not exist. The following interactions are derived from pharmacological principles and pharmaceutical studies of the isolated alkaloids. '''CYP3A4 inhibitors:''' [[glossary:grapefruit-juice]] increases scopolamine exposure (AUC) to approximately 142% of control and prolongs [[glossary:tmax|time to peak concentration]], via [[glossary:inhibition]] of intestinal CYP3A [[glossary:metabolism]]{{cite|pubmed=16175141|anchor=8d65596d}}. Other [[glossary:cyp3a4]] [[glossary:inhibitor|inhibitors]] (ketoconazole, clarithromycin, ritonavir) would produce analogous effects on scopolamine-containing preparations. '''Additive anticholinergic burden:''' Co-administration with other anticholinergic agents — first-generation antihistamines ([[substance:diphenhydramine]]), tricyclic [[substance_class:psychoactive/antidepressant|antidepressants]] (amitriptyline), [[substance_class:psychoactive/antipsychotic|antipsychotics]] (olanzapine), and urological agents (oxybutynin) — carries risk of synergistic anticholinergic toxicity. '''CNS depressants:''' Additive [[glossary:central-nervous-system|CNS]] [[effect:depression]] with [[substance:alcohol]], [[substance_class:psychoactive/opioid|opioids]], and [[substance_class:chemical/benzodiazepine|benzodiazepines]]. CNS depressant [[glossary:co-ingestion|co-ingestion]] was noted in a fatal scopolamine case{{cite|doi=10.1007/s00414-021-02583-2|anchor=0d3d0f2d}}. '''Cholinesterase inhibitors:''' Direct pharmacodynamic [[glossary:antagonism]] with donepezil, rivastigmine, and [[substance:galantamine]] — reduces [[glossary:efficacy]] of both agents. Clinically significant in dementia patients, where inadvertent anticholinergic exposure from herbal products can undermine therapeutic benefit. '''MAO inhibitors:''' A potential interaction based on shared CNS pathways has been proposed. No specific clinical data exist for ''Mandragora'' preparations with MAOIs{{flag|citation-needed}}. ====Contraindications==== '''Cardiac disease:''' Supraventricular tachycardia exceeding 170 bpm has been documented in ''Mandragora'' poisoning{{cite|doi=10.1186/1757-1626-2-9331|anchor=5ec56121}}. Pre-existing [[glossary:arrhythmia|cardiac arrhythmia]], coronary artery disease, or heart failure constitutes an absolute [[glossary:contraindication]]. '''Elderly individuals:''' Enhanced anticholinergic [[glossary:sensitivity]] in older adults is well established. Severe scopolamine toxicity via transdermal patch was documented in a 66-year-old patient{{cite|doi=10.1093/milmed/usz086|anchor=60f82a64}}. '''Pregnancy:''' Scopolamine crosses the placenta{{cite|pubmed=16175141|anchor=16fc6b09}}. Uncontrolled alkaloid exposure from plant preparations and risk of maternal anticholinergic [[glossary:toxidrome]] constitute a contraindication. '''Concurrent anticholinergic medications:''' Patients taking any [[glossary:medication]] with anticholinergic properties face additive toxicity risk. '''Concurrent cholinesterase inhibitor therapy:''' Direct pharmacodynamic antagonism creates dual harm — reduced therapeutic efficacy and risk of anticholinergic breakthrough. '''Hepatic impairment:''' Scopolamine undergoes extensive CYP3A4 metabolism{{cite|pubmed=16175141|anchor=fb5c8ba7}}. [[glossary:hepatic-impairment|Impaired hepatic function]] increases systemic exposure and prolongs effect duration. '''Pediatric populations:''' Children are particularly vulnerable to anticholinergic toxidrome{{flag|safety-citation-needed}}. '''Glaucoma:''' Anticholinergic mydriasis can precipitate acute angle-closure glaucoma{{flag|citation-needed}}. '''Urinary obstruction:''' Anticholinergic urinary retention can exacerbate prostatic hypertrophy or obstructive uropathy{{flag|citation-needed}}.

====Toxicity==== No [[glossary:lethal-dose|LD50]] has been established for whole-plant ''Mandragora'' preparations. The safety profile derives entirely from clinical [[glossary:case-report|case reports]]. Acute poisoning produces the classic '''anticholinergic toxidrome''': [[glossary:body-temperature]] rises as sweating stops, skin becomes hot and flushed, pupils dilate, and [[glossary:excited-delirium]] with [[glossary:hallucination|hallucinations]] and [[effect:amnesia]] sets in{{cite|doi=10.1021/acschemneuro.8b00615|anchor=0f472b4d}}. Two adults in Crete developed [[glossary:heart-rate|heart rates]] of 170–190 bpm, [[effect:nausea]], [[effect:visual-acuity-suppression]], and flushed skin after eating ''Mandragora'' berries mistaken for borage. [[glossary:tachycardia]] persisted for 5 days; treatment required physostigmine and gastric lavage. Both recovered fully within 10 days{{cite|doi=10.1186/1757-1626-2-9331|anchor=7b067b77}}. A fatal case involving smoked [[substance:scopolamine]] tablets showed [[glossary:fatality|lethality]] at peripheral [[glossary:plasma-concentration|blood concentrations]] of 14 ng/mL, with brain and lung swelling on pathology{{cite|doi=10.1007/s00414-021-02583-2|anchor=c5d4097f}}. This is not a ''Mandragora'' preparation, but it establishes that scopolamine at toxic concentrations can be directly lethal. ''Mandragora'' is wild-harvested with no standardized preparations, no regulatory oversight, and no quality control: * '''Misidentification as food plants:''' berries and leaves mistaken for borage or spinach — the most documented poisoning pathway{{cite|doi=10.1186/1757-1626-2-9331|anchor=91b76153}} * '''Commercial mislabeling:''' products sold as "mandrake" in North America may contain ''Podophyllum peltatum'' — a [[glossary:cytotoxicity|cytotoxic]] plant with a radically different [[glossary:toxicity|toxicity profile]]{{cite|pubmed=9308513|anchor=95629f86}} * '''Batch variability:''' alkaloid content varies by species, plant part, developmental stage, and growing conditions — no standardization is possible from wild material * '''No testing infrastructure:''' no Certificate of Analysis programs or regulated supply chain exist{{flag|citation-needed}} ====Psychological Risks==== The [[substance_class:psychoactive/deliriant]] syndrome causes global cognitive disorganization, vivid hallucinations indistinguishable from reality, agitated [[effect:confusion]], and complete or partial amnesia{{cite|doi=10.1021/acschemneuro.8b00615|anchor=557ea524}}. Reality testing is abolished — the user cannot recognize they are hallucinating during the episode. Severe psychological [[glossary:distress]] is the norm, not the exception. The experience is consistently described as frightening and dysphoric{{cite|doi=10.1371/journal.pone.0247688|anchor=80d404a2}}. No dose strategy reliably produces psychoactive effects without risk of severe toxicity. Persistent psychological effects from acute anticholinergic [[glossary:intoxication]] have not been systematically studied{{flag|citation-needed}}. ====Tolerance & Dependence==== No published data on [[glossary:tolerance]], [[glossary:physical-dependence]], or [[glossary:withdrawal]] exist for ''Mandragora'' preparations specifically. Tolerance to anticholinergic effects is recognized with repeated pharmaceutical use of scopolamine and atropine, but no physical dependence syndrome or withdrawal has been documented for anticholinergic agents as a class. Compulsive use is unlikely. A survey of [[substance_class:psychoactive/hallucinogen]] users found knowledge of anticholinergic Solanaceae largely lost, attributed to severe toxicity and unpleasant effects{{cite|doi=10.1371/journal.pone.0247688|anchor=fe4098fd}}. ====Drug Interactions==== '''CYP3A4 inhibitors:''' [[glossary:grapefruit-juice]] increases scopolamine exposure to roughly 142% of normal and delays peak concentration, by blocking intestinal [[glossary:metabolism]]{{cite|pubmed=16175141|anchor=41745a54}}. Other [[glossary:cyp3a4]] [[glossary:inhibitor|inhibitors]] — ketoconazole, clarithromycin, ritonavir — produce similar effects on scopolamine-containing preparations. '''Additive anticholinergic load:''' Combining with other anticholinergic agents — antihistamines ([[substance:diphenhydramine]]), tricyclic [[substance_class:psychoactive/antidepressant|antidepressants]] (amitriptyline), [[substance_class:psychoactive/antipsychotic|antipsychotics]] (olanzapine), or bladder [[glossary:medication|medications]] (oxybutynin) — risks synergistic toxicity. '''CNS depressants:''' Combining with [[substance:alcohol]], [[substance_class:psychoactive/opioid|opioids]], or [[substance_class:chemical/benzodiazepine|benzodiazepines]] compounds [[glossary:central-nervous-system|CNS]] [[effect:depression]]. [[glossary:co-ingestion]] was noted in a fatal scopolamine case{{cite|doi=10.1007/s00414-021-02583-2|anchor=efc6c80a}}. '''Cholinesterase inhibitors:''' Direct pharmacological [[glossary:antagonism]] with dementia medications — donepezil, rivastigmine, and [[substance:galantamine]]. Each agent undermines the other's effects; clinically significant for dementia patients. '''MAO inhibitors:''' A potential interaction based on shared CNS pathways has been proposed. No specific clinical data exist for ''Mandragora'' preparations with MAOIs{{flag|citation-needed}}. ====Contraindications==== * '''Cardiac disease:''' Heart rates above 170 bpm documented in ''Mandragora'' poisoning{{cite|doi=10.1186/1757-1626-2-9331|anchor=5538cd65}} — existing [[glossary:arrhythmia]], coronary disease, or heart failure is an absolute [[glossary:contraindication]]. * '''Elderly individuals:''' Heightened anticholinergic [[glossary:sensitivity]] in older adults; severe toxicity from a transdermal scopolamine patch documented in a 66-year-old patient{{cite|doi=10.1093/milmed/usz086|anchor=64b808a0}}. * '''Pregnancy:''' Scopolamine crosses the placenta{{cite|pubmed=16175141|anchor=2c5b4391}} — uncontrolled alkaloid exposure from plant preparations is contraindicated. * '''Concurrent anticholinergic medications:''' Additive toxicity risk. * '''Cholinesterase inhibitor therapy:''' Dual harm — reduced therapeutic [[glossary:efficacy]] and risk of anticholinergic breakthrough. * '''Hepatic impairment:''' Reduced liver metabolism increases systemic scopolamine exposure and prolongs effects{{cite|pubmed=16175141|anchor=d98d51da}}. * '''Children:''' Particularly vulnerable to anticholinergic [[glossary:toxidrome]]{{flag|safety-citation-needed}}. * '''Glaucoma:''' Anticholinergic [[effect:pupil-dilation]] can [[glossary:trigger]] acute angle-closure glaucoma{{flag|citation-needed}}. * '''Urinary obstruction:''' Anticholinergic urinary retention worsens prostatic hypertrophy or obstructive uropathy{{flag|citation-needed}}.

No published dose-characterization data exist for any ''Mandragora'' preparation, and no standardized commercial supply chain has been established. All preparations carry an extremely narrow and unpredictable margin between perceptible effect and severe anticholinergic [[glossary:toxicity]]. The following documents historically recorded and real-world exposure forms rather than recommended preparations. ====Root decoction in wine==== The oldest documented preparation form. Dioscorides recorded approximately 1 cyathus (~45 mL) of root decoction boiled in wine and reduced to one-third volume, administered orally before surgical procedures. Alkaloid concentration in this preparation depends entirely on the root material, species, and boiling duration. This is a traditional-use account without clinical confirmation — no safe dose has been established, and no modern pharmacokinetic data exist for this preparation. ====Topical ointment==== Historical "witches' ointment" (''unguentum sabbati'') preparations combined mandrake with belladonna and henbane, rendered in animal fat and applied transdermally. [[substance:scopolamine]] is pharmacologically capable of transdermal [[glossary:absorption]] — pharmaceutical scopolamine patches achieve [[glossary:steady-state|steady-state]] [[glossary:plasma-concentration|plasma concentrations]] of 56–245 pg/mL over 72 hours{{cite|pubmed=16175141|anchor=4af8dc47}}{{cite|doi=10.1021/acs.molpharmaceut.1c00238|anchor=216bc75b}}. No pharmacokinetic data exist for transdermal absorption from traditional ointment preparations specifically, and alkaloid delivery from crude plant-fat mixtures cannot be compared to pharmaceutical patch formulations. ====Raw plant material (accidental ingestion)==== The dominant real-world exposure pathway is accidental consumption of berries or leaves mistaken for edible plants such as borage{{cite|doi=10.1186/1757-1626-2-9331|anchor=67f07e53}}. Documented clinical cases involved eating berries believed to be food or aphrodisiac{{cite|doi=10.1016/j.jemermed.2011.03.023|anchor=cf23d8eb}}. The quantity of [[glossary:plant-material]] that produces clinical toxicity is unknown and varies by species, plant part, and individual alkaloid content. No threshold, common, or strong [[glossary:dose-range|dose ranges]] can be stated for any raw plant material form. ====Oral pharmacokinetics (isolated alkaloids)==== No pharmacokinetic data exist for whole-plant ''Mandragora'' preparations in humans. For pharmaceutical scopolamine administered orally: tmax approximately 0.5 hours; oral [[glossary:bioavailability]] 3–27% due to high [[glossary:first-pass-metabolism|first-pass]] [[glossary:metabolism|hepatic metabolism]] via [[glossary:cyp3a4]]; only 2.6% excreted unchanged in urine{{cite|pubmed=16175141|anchor=e2ae674f}}. Both scopolamine and hyoscyamine cross the [[glossary:blood-brain-barrier]] and placenta readily{{cite|pubmed=16175141|anchor=0f756f89}}. Per-preparation dose tiers, timelines, and bioavailability data are absent from the published literature for all ''Mandragora'' preparations. No standardized commercial supply chain exists.

===Forms & Identification=== ''Mandragora'' has no standardized commercial preparations and no regulated supply chain. Products sold as "mandrake" in North America may contain ''Podophyllum peltatum'' — a [[glossary:cytotoxicity|cytotoxic]] plant with an entirely different [[glossary:toxicity|toxicity profile]]{{cite|pubmed=9308513|anchor=2fe538d3}}. Botanical identification is critical. The berries and leaves closely resemble edible species — [[glossary:misidentification]] is the most documented poisoning pathway{{cite|doi=10.1186/1757-1626-2-9331|anchor=19a3b1fd}}. Confirm identification with a qualified botanist before handling wild material. No [[glossary:reagent-kit|reagent test]] or field kit exists for detecting [[substance_class:chemical/tropane]] alkaloid content in raw [[glossary:plant-material]]. ===Set & Setting=== Anticholinergic [[effect:delirium]] abolishes reality testing — the user cannot recognize the experience as drug-induced and cannot make safety decisions during the episode{{cite|doi=10.1021/acschemneuro.8b00615|anchor=20bfaec0}}. Environmental preparation cannot prevent this. If exposure occurs, a sober, informed companion able to prevent [[glossary:self-harm]] and contact emergency services is essential. The setting must remove access to roads, bodies of water, heights, and sharp objects. {{Guideline}} ===Guidelines=== * '''No safe recreational dose has been established for any ''Mandragora'' preparation.''' The margin between perceptible effect and severe anticholinergic toxicity is extremely narrow and unpredictable due to uncharacterized alkaloid variability. * '''Never consume wild plant material without expert botanical identification.''' ''Mandragora'' berries are a documented cause of accidental poisoning when mistaken for edible plants. * '''Never combine with other anticholinergic agents''' — including over-the-counter antihistamines ([[substance:diphenhydramine]], dimenhydrinate), sleep aids, and tricyclic [[substance_class:psychoactive/antidepressant|antidepressants]]. Additive toxicity is the expected outcome. * '''Never combine with CNS depressants''' ([[substance:alcohol]], [[substance_class:psychoactive/opioid|opioids]], [[substance_class:chemical/benzodiazepine|benzodiazepines]]). [[glossary:central-nervous-system|CNS]] depressant [[glossary:co-ingestion|co-ingestion]] was noted in a fatal [[substance:scopolamine]] case. * '''Avoid CYP3A4 inhibitors''' — including [[glossary:grapefruit-juice]] — which increase scopolamine exposure by approximately 42%{{cite|pubmed=16175141|anchor=d6ebd381}}. * '''Inform a sober companion''' of what was taken, the expected duration, and when to call emergency services. * '''Physostigmine awareness:''' physostigmine is the specific antidote for anticholinergic [[glossary:toxidrome]]. Emergency physicians may not consider it without being told the substance involved. {{/Guideline}} {{Emergency}} ===Emergency Response=== '''Red flags requiring immediate emergency response:''' * [[glossary:heart-rate]] above 150 bpm or irregular heartbeat * [[glossary:body-temperature]] rising with hot, dry skin and inability to sweat * Severe [[glossary:agitation]], [[effect:confusion]], or unresponsiveness * [[glossary:seizure|Seizures]] * Difficulty breathing '''Immediate steps:''' * Call emergency services (911 / 112 / local equivalent) immediately. * Do not leave the person alone — they cannot distinguish reality from [[glossary:hallucination]] and may harm themselves. * Move the person to a cool environment. Apply cool water to skin if body temperature is elevated. * Do not induce [[effect:vomiting]] unless instructed by poison control. * Do not physically restrain unless the person is in immediate danger of self-harm. '''What to tell the dispatcher:''' * The person consumed ''Mandragora'' (mandrake) — a plant containing anticholinergic tropane alkaloids (hyoscyamine, scopolamine). * Approximate amount and time of [[glossary:ingestion]] if known. * Current symptoms: heart rate, temperature, pupil size, mental state. * '''Physostigmine''' is the specific antidote — mention this to ensure the emergency team considers it. [[glossary:good-samaritan-law|Good Samaritan laws]] exist in many jurisdictions and provide legal protection for those seeking emergency help. {{/Emergency}} {{Aftercare}} ===Aftercare & Integration=== Anticholinergic delirium typically produces dense [[effect:amnesia]] — the person may have little or no memory of the experience. Residual confusion, visual [[glossary:disturbance]] from persistent [[effect:pupil-dilation]], and [[glossary:fatigue]] may continue for 24–48 hours after acute symptoms resolve. Rehydrate gradually. Anticholinergic effects suppress saliva and fluid regulation — oral rehydration with electrolytes is appropriate once the person can swallow safely. Monitor heart rhythm. Supraventricular [[glossary:tachycardia]] persisted for up to 5 days in documented ''Mandragora'' ingestion cases{{cite|doi=10.1186/1757-1626-2-9331|anchor=266e2658}}. Seek medical follow-up if heart rate remains elevated or irregular. Liver [[glossary:enzyme]] monitoring may be warranted — documented cases showed liver enzyme [[glossary:elevation]] normalizing within 10 days{{cite|doi=10.1186/1757-1626-2-9331|anchor=5713ec2c}}. The frightening character of anticholinergic delirium may produce acute [[effect:anxiety]] in the days following exposure. Professional psychological support is appropriate if [[glossary:distress]] persists. {{/Aftercare}} {{Recovery}} ===Recovery & Support=== Compulsive use of ''Mandragora'' is extremely rare given the characteristically unpleasant experience{{cite|doi=10.1371/journal.pone.0247688|anchor=e559c440}}. Most exposures are accidental rather than intentional. For anyone experiencing distress following anticholinergic exposure: * '''Poison Control''' (US): 1-800-222-1222 * '''SAMHSA National Helpline''' (US): 1-800-662-4357 (free, confidential, 24/7) * '''NHS 111''' (UK): for non-emergency medical advice following plant exposure * '''European emergency number:''' 112 If anticholinergic plant exposure was intentional and reflects a pattern of self-harm or [[glossary:substance-use]], professional evaluation is warranted. Anticholinergic agents do not produce [[glossary:physical-dependence]], but intentional use of [[substance_class:psychoactive/deliriant]] substances may indicate underlying needs that benefit from clinical support. {{/Recovery}}

===Forms & Identification=== ''Mandragora'' has no standardized commercial preparations and no regulated supply chain. Products sold as "mandrake" in North America may contain ''Podophyllum peltatum'' — an entirely different plant with [[glossary:cytotoxicity|cytotoxic]] rather than anticholinergic properties{{cite|pubmed=9308513|anchor=6c54f896}}. No Certificate of Analysis programs, ISO-accredited laboratory testing, or quality standards exist for ''Mandragora'' products. Botanical identification is critical: the plant's berries and leaves closely resemble edible species such as borage and spinach, and [[glossary:misidentification]] is the most documented poisoning pathway{{cite|doi=10.1186/1757-1626-2-9331|anchor=153ce7f4}}. Anyone handling wild ''Mandragora'' should confirm identification with a qualified botanist. No [[glossary:reagent-kit|reagent test]] or field kit exists for detecting [[substance_class:chemical/tropane]] alkaloid content in raw [[glossary:plant-material]]. ===Set & Setting=== Anticholinergic [[effect:delirium]] abolishes [[glossary:insight]] and reality testing — the user cannot recognize the experience as drug-induced and cannot make safety decisions during the episode{{cite|doi=10.1021/acschemneuro.8b00615|anchor=36c8f704}}. This fundamentally distinguishes ''Mandragora'' from substances where [[glossary:set-and-setting]] modulate experience quality. Environmental preparation cannot mitigate the core risk because the user loses all capacity for self-regulation during [[glossary:intoxication]]. If exposure occurs, a sober, informed companion who can prevent [[glossary:self-harm]] and contact emergency services is essential. The setting must be physically safe — no access to roads, bodies of water, heights, or sharp objects. The companion should be briefed on anticholinergic [[glossary:toxidrome]] recognition and emergency response. {{Guideline}} ===Guidelines=== * '''No safe recreational dose has been established for any ''Mandragora'' preparation.''' The margin between perceptible effect and severe anticholinergic [[glossary:toxicity]] is extremely narrow and unpredictable due to uncharacterized alkaloid variability. * '''Never consume wild plant material without expert botanical identification.''' ''Mandragora'' berries are a documented cause of accidental poisoning when mistaken for edible plants. * '''Never combine with other anticholinergic agents''' — including over-the-counter antihistamines ([[substance:diphenhydramine]], dimenhydrinate), sleep aids, and tricyclic [[substance_class:psychoactive/antidepressant|antidepressants]]. Additive toxicity is the expected outcome. * '''Never combine with CNS depressants''' ([[substance:alcohol]], [[substance_class:psychoactive/opioid|opioids]], [[substance_class:chemical/benzodiazepine|benzodiazepines]]). [[glossary:central-nervous-system|CNS]] depressant [[glossary:co-ingestion|co-ingestion]] was noted in a fatal [[substance:scopolamine]] case. * '''Avoid CYP3A4 inhibitors''' — including [[glossary:grapefruit-juice]] — which increase scopolamine exposure by approximately 42%{{cite|pubmed=16175141|anchor=bd479397}}. * '''Inform a sober companion''' of what was taken, the expected duration, and when to call emergency services. * '''Physostigmine awareness:''' physostigmine is the specific antidote for anticholinergic toxidrome. Emergency physicians may not immediately consider it without being told the substance involved. {{/Guideline}} {{Emergency}} ===Emergency Response=== '''Red flags requiring immediate emergency response:''' * [[glossary:heart-rate]] above 150 bpm or irregular heartbeat * [[glossary:body-temperature]] rising with hot, dry skin and inability to sweat * Severe [[glossary:agitation]], [[effect:confusion]], or unresponsiveness * [[glossary:seizure|Seizures]] * Difficulty breathing '''Immediate steps:''' * Call emergency services (911 / 112 / local equivalent) immediately. * Do not leave the person alone — they cannot distinguish reality from [[glossary:hallucination]] and may harm themselves. * Move the person to a cool environment. Apply cool water to skin if body temperature is elevated. * Do not induce [[effect:vomiting]] unless instructed by poison control. * Do not physically restrain unless the person is in immediate danger of self-harm. '''What to tell the dispatcher:''' * The person consumed ''Mandragora'' (mandrake) — a plant containing anticholinergic tropane alkaloids (hyoscyamine, scopolamine). * Approximate amount and time of [[glossary:ingestion]] if known. * Current symptoms: heart rate, temperature, pupil size, mental state. * '''Physostigmine''' is the specific antidote — mention this to ensure the emergency team considers it. [[glossary:good-samaritan-law|Good Samaritan laws]] exist in many jurisdictions and provide legal protection for those seeking emergency help. {{/Emergency}} {{Aftercare}} ===Aftercare & Integration=== Anticholinergic delirium typically produces dense [[effect:amnesia]] — the person may have little or no memory of the experience. Residual confusion, visual [[glossary:disturbance]] from persistent [[effect:pupil-dilation]], and [[glossary:fatigue]] may continue for 24–48 hours after acute symptoms resolve. Rehydrate gradually. Anticholinergic effects suppress [[effect:salivation]] and normal fluid regulation — oral rehydration with electrolytes is appropriate once the person can swallow safely. Monitor heart rhythm. In documented cases, supraventricular [[glossary:tachycardia]] persisted for up to 5 days after ''Mandragora'' ingestion{{cite|doi=10.1186/1757-1626-2-9331|anchor=d9473d45}}. Seek medical follow-up if heart rate remains elevated or irregular. Liver [[glossary:enzyme]] monitoring may be warranted — documented cases showed liver enzyme [[glossary:elevation]] that normalized within 10 days{{cite|doi=10.1186/1757-1626-2-9331|anchor=f7369556}}. The dysphoric and frightening character of anticholinergic delirium may produce acute [[effect:anxiety]] or [[glossary:distress]] in the days following exposure. Professional psychological support is appropriate if distress persists. {{/Aftercare}} {{Recovery}} ===Recovery & Support=== Compulsive use of ''Mandragora'' is extremely rare given the characteristically unpleasant experience{{cite|doi=10.1371/journal.pone.0247688|anchor=4af9d3aa}}. Most exposures are accidental rather than intentional. For anyone experiencing distress following anticholinergic exposure: * '''Poison Control''' (US): 1-800-222-1222 * '''SAMHSA National Helpline''' (US): 1-800-662-4357 (free, confidential, 24/7) * '''NHS 111''' (UK): for non-emergency medical advice following plant exposure * '''European emergency number:''' 112 If anticholinergic plant exposure was intentional and reflects a pattern of self-harm or [[glossary:substance-use-disorder]], professional evaluation is warranted. Anticholinergic agents do not produce [[glossary:physical-dependence]], but intentional use of [[substance_class:psychoactive/deliriant]] substances may indicate underlying psychological needs that benefit from clinical support. {{/Recovery}}

===Receptor pharmacology=== The dominant alkaloids in ''Mandragora'' — hyoscyamine, atropine, and (in ''M. autumnalis'') [[substance:scopolamine]] — are competitive [[glossary:antagonist|antagonists]] at [[glossary:muscarinic-acetylcholine-receptor|muscarinic acetylcholine receptors]] (M₁–M₅){{cite|doi=10.1021/acschemneuro.8b00615|anchor=fdfd911d}}{{cite|doi=10.1007/s13659-022-00357-w|anchor=0f1931c9}}. This mechanism is thoroughly characterized for the isolated compounds, which serve as the pharmacological basis for the plant's effects. No serotonergic or glutamatergic [[glossary:receptor]] involvement has been documented; the hallucinatory profile is exclusively anticholinergic in origin. Scopolamine has greater [[glossary:central-nervous-system|CNS]] penetrance than hyoscyamine or its [[glossary:racemic-mixture]] atropine, producing more pronounced [[effect:sedation]], [[effect:amnesia]], and [[glossary:hallucination|hallucinations]] at lower doses relative to peripheral effects. Hyoscyamine and atropine produce prominent peripheral anticholinergic effects: [[effect:pupil-dilation]], cycloplegia, [[effect:dry-mouth]], anhidrosis, [[glossary:tachycardia]], urinary retention, decreased bowel motility, and bronchodilation. ===Deliriant mechanism=== At supratherapeutic doses, central muscarinic [[glossary:blockade]] produces a characteristic '''deliriant syndrome''' — qualitatively distinct from classic [[substance_class:psychoactive/psychedelic]] [[substance_class:psychoactive/hallucinogen|hallucinogens]]{{cite|doi=10.1021/acschemneuro.8b00615|anchor=99ee7f78}}. This syndrome is characterized by: * Disoriented, confused, [[glossary:excited-delirium]] * Vivid but fragmented hallucinations, frequently visual and tactile * Complete or partial amnesia for the episode * Inability to distinguish hallucinated content from reality (''reality testing is abolished'') The experiential character differs fundamentally from serotonergic psychedelia: users do not typically report geometric visual phenomena, emotional deepening, or mystical states. Instead, the hallucinations are mundane in content (conversing with absent persons, interacting with nonexistent objects), seamlessly integrated into perceived reality, and accompanied by global cognitive disorganization. ===Pharmacokinetics of isolated alkaloids=== No published pharmacokinetic data exist for whole-plant ''Mandragora'' preparations in humans. The following data derive from pharmaceutical scopolamine and atropine studies: '''Scopolamine (oral):''' tmax approximately 0.5 hours; oral [[glossary:bioavailability]] 3–27% due to high [[glossary:first-pass-metabolism]] via CYP3A-mediated oxidative N-demethylation in the intestinal wall and liver; only 2.6% excreted unchanged in urine{{cite|pubmed=16175141|anchor=0d4abfc2}}. '''Scopolamine (transdermal patch):''' cmax approximately 100 pg/mL (range 11–240 pg/mL) at approximately 8 hours post-application; [[glossary:steady-state|steady-state]] [[glossary:plasma-concentration|plasma concentrations]] maintained at 56–245 pg/mL over 72 hours{{cite|pubmed=16175141|anchor=bfcb4b79}}{{cite|doi=10.1021/acs.molpharmaceut.1c00238|anchor=312f8d63}}. '''CYP enzyme involvement:''' Scopolamine undergoes oxidative N-demethylation primarily via [[glossary:cyp3a4]]. [[glossary:grapefruit-juice]], a CYP3A intestinal [[glossary:inhibitor]], increases scopolamine AUC to approximately 142% of control and significantly prolongs tmax{{cite|pubmed=16175141|anchor=b6665f91}}. '''Blood-brain barrier:''' Both scopolamine and hyoscyamine cross the [[glossary:blood-brain-barrier]] readily. The placenta is also permeable to these alkaloids{{cite|pubmed=16175141|anchor=b63db501}}. ===Neuroimaging and open questions=== No neuroimaging studies (fMRI, PET, EEG) using ''Mandragora'' preparations as administered have been published. Neuroimaging data for pharmaceutical scopolamine exist in the Alzheimer's disease research context but are not directly applicable to the plant's polypharmacological matrix. Open questions include: (1) the [[glossary:pharmacokinetic-interaction]] between [[substance_class:chemical/tropane]] alkaloids and the plant's non-alkaloid constituents (withanolides, coumarins) in whole-plant preparations; (2) whether the alkaloid ratio differences between ''M. officinarum'' (hyoscyamine-dominant) and ''M. autumnalis'' (mixed hyoscyamine-scopolamine) produce qualitatively distinct [[glossary:intoxication]] profiles; and (3) the preparation-specific [[glossary:pharmacokinetics]] of ''Mandragora'' — particularly transdermal [[glossary:absorption]] from historical ointment preparations — which remain entirely uncharacterized.

''Mandragora'' species are [[glossary:unscheduled|not scheduled]] under any UN [[glossary:drug-control]] convention (1961, 1971, or 1988). The principal alkaloids hyoscyamine and [[substance:scopolamine]] are also unscheduled internationally, though both are regulated as prescription-only medicines in most countries when manufactured as pharmaceutical products. Atropine and scopolamine appear on the WHO List of Essential Medicines{{cite|doi=10.1007/s13659-022-00357-w|anchor=b39e52c9}}. In the United States, ''Mandragora officinarum'' is legal to possess, cultivate, and distribute under federal law, though Louisiana prohibits it for [[glossary:human-consumption]] under state law{{cite|name=erowid-mandrake-law|type=book|author=Erowid|year=2024|title=Erowid Mandrake (Mandragora officinarum) Law Vault|anchor=d103f50c}}. In the United Kingdom, ''M. autumnalis'' used in medicinal products is prescription-only{{cite|name=erowid-mandrake-law|type=book|author=Erowid|year=2024|title=Erowid Mandrake (Mandragora officinarum) Law Vault|anchor=c3d52195}}. The European Medicines Agency does not recognize any ''Mandragora'' species as an approved herbal medicinal product{{cite|name=erowid-mandrake-law|type=book|author=Erowid|year=2024|title=Erowid Mandrake (Mandragora officinarum) Law Vault|anchor=18ea9859}}. Standard drug screening panels do not detect hyoscyamine or scopolamine — forensic confirmation requires specialized LC-MS/MS analysis{{cite|doi=10.1016/j.jpba.2019.112945|anchor=8f1386a2}}{{cite|pubmed=31573667|anchor=63937845}}. {{Warning}} Legal status changes frequently. This overview reflects the status as of the article's last update and is not legal advice. Verify current law in the relevant jurisdiction before acting on this information. {{/Warning}}

''Mandragora'' species are [[glossary:unscheduled|not scheduled]] under any of the three major UN [[glossary:drug-control|drug control conventions]] (1961, 1971, 1988). The principal alkaloids hyoscyamine and [[substance:scopolamine]] are also unscheduled internationally, though both are controlled as prescription-only pharmaceutical agents in most jurisdictions when manufactured as medicines. Atropine and scopolamine appear on the WHO List of Essential Medicines{{cite|doi=10.1007/s13659-022-00357-w|anchor=1d6683dd}}. Regulatory treatment varies by jurisdiction, with most countries imposing no specific restrictions on the plant itself.

Jurisdiction	Status	Notes
United States (federal)	Uncontrolled	''Mandragora officinarum'' and its extracts are not scheduled under the Controlled Substances Act. Legal to possess, cultivate, buy, and distribute. Supplement sales must conform to DSHEA{{cite|name=erowid-mandrake-law|type=book|author=Erowid|year=2024|title=Erowid Mandrake (Mandragora officinarum) Law Vault|anchor=bdd6c6c8}}.
Louisiana (US state)	Prohibited for human consumption	Louisiana Act No. 159 (effective August 8, 2005) names ''Mandragora officinarum'' among 40 plants prohibited when intended for human consumption. Aesthetic, landscaping, and decorative purposes are exempt{{cite|name=erowid-mandrake-law|type=book|author=Erowid|year=2024|title=Erowid Mandrake (Mandragora officinarum) Law Vault|anchor=3da488cc}}.
Other US states	No specific bans identified	No state-level prohibitions on ''Mandragora'' were identified in published literature{{flag|citation-needed}}.
United Kingdom	Prescription only (''M. autumnalis'' in medicines)	The Prescription Only Medicines (Human Use) Order 1997 identifies ''M. autumnalis'' as making medicinal products prescription-only. Whether this extends to ''M. officinarum'' is unclear{{cite|name=erowid-mandrake-law|type=book|author=Erowid|year=2024|title=Erowid Mandrake (Mandragora officinarum) Law Vault|anchor=dd813549}}.
European Union	No EU-wide scheduling	The European Medicines Agency does not recognize any ''Mandragora'' species as an approved herbal medicinal product{{cite|name=erowid-mandrake-law|type=book|author=Erowid|year=2024|title=Erowid Mandrake (Mandragora officinarum) Law Vault|anchor=4e633272}}.
Germany	No specific data found	No regulatory data specific to ''Mandragora'' were identified{{flag|citation-needed}}.
Australia	No specific data found	No regulatory data specific to ''Mandragora'' were identified{{flag|citation-needed}}.
Israel	No specific data found	No regulatory data specific to ''Mandragora'' were identified{{flag|citation-needed}}.

===Detection=== Standard immunoassay drug panels do not detect hyoscyamine or scopolamine. Forensic or clinical confirmation requires specific LC-MS/MS methodology{{cite|doi=10.1016/j.jpba.2019.112945|anchor=7326b5a5}}{{cite|pubmed=31573667|anchor=2aa04411}}. Anticholinergic syndrome is typically diagnosed clinically by symptom pattern rather than toxicological screening.

The experiential character of ''Mandragora'' [[glossary:intoxication]] is defined by the anticholinergic [[substance_class:psychoactive/deliriant]] mechanism rather than any serotonergic, glutamatergic, or endocannabinoid pathway. The dominant phenomenological feature is the abolition of reality testing: hallucinated content — typically mundane in character, such as conversations with absent persons or interactions with nonexistent objects — is seamlessly integrated into perceived reality, with no subjective [[glossary:awareness]] that the experience is drug-induced. This is accompanied by global cognitive disorganization, agitated [[effect:confusion]], profound [[effect:amnesia]], and prominent peripheral anticholinergic effects ([[effect:dry-mouth]], [[glossary:tachycardia]], [[effect:pupil-dilation]], [[glossary:hyperthermia]]). The species of ''Mandragora'' consumed determines the alkaloid mix and likely modulates the central-to-peripheral effect ratio, though this has not been empirically compared. ''Mandragora'' intoxication sits within the same pharmacological [[glossary:class-a|class as]] ''Datura stramonium'', ''Atropa belladonna'', and ''Hyoscyamus niger'' — anticholinergic Solanaceae whose psychoactive effects arise from [[glossary:muscarinic-acetylcholine-receptor]] [[glossary:blockade]] rather than [[glossary:monoamine]] or [[substance_class:chemical/indoleamine]] [[glossary:modulation]]. The experience is qualitatively distinct from [[glossary:serotonergic-psychedelics|classical psychedelics]], [[substance_class:psychoactive/dissociative|dissociatives]], and [[substance:cannabis]]: there is no geometric visual patterning, no emotional deepening or mystical [[glossary:phenomenology]], and no preserved [[glossary:insight]] during the episode.

===Toxicity=== No [[glossary:lethal-dose|LD50]] has been established for whole-plant ''Mandragora'' preparations in any species. No controlled [[glossary:toxicity]] data exist. The safety profile is characterized entirely from clinical [[glossary:case-report|case reports]] and [[glossary:inference|extrapolation]] from pharmaceutical anticholinergic literature. ====Anticholinergic toxidrome==== Acute ''Mandragora'' poisoning produces the classic anticholinergic toxidrome{{cite|doi=10.1021/acschemneuro.8b00615|anchor=dbba5be4}}{{flag|additional-citations-needed}}: * '''Hyperthermia''' — anhidrosis prevents thermoregulation * '''Dry mucous membranes''' — absent [[effect:salivation]], urinary retention * '''Cutaneous flushing''' — vasodilation * '''Mydriasis and cycloplegia''' — blurred near vision, [[effect:light-sensitivity]] * '''Delirium''' — [[glossary:agitation]], [[glossary:hallucination|hallucinations]], [[effect:amnesia]] ====Documented clinical cases==== Two adults from the same family in Crete presented after eating ''Mandragora'' berries mistaken for borage. Both developed [[effect:nausea]], [[effect:dizziness]], [[effect:visual-acuity-suppression]], [[effect:dry-mouth]], [[effect:headache]], [[effect:vomiting]], flushed skin, reactive [[effect:pupil-dilation]], and supraventricular [[glossary:tachycardia]] with pulse rates of 190 and 170 bpm. ECG confirmed supraventricular tachycardia, which persisted for 5 days. Treatment consisted of physostigmine 1 mg IV per day following gastric lavage. Neurological symptoms resolved within 2 days; [[glossary:liver-enzymes]] normalized within 10 days. Both patients recovered fully. No confirmatory [[glossary:toxicology]] was performed{{cite|doi=10.1186/1757-1626-2-9331|anchor=260cb512}}{{flag|additional-citations-needed}}. A separate case documented accidental poisoning after [[glossary:ingestion]] of ''M. officinarum'' berries believed to be aphrodisiac, with diagnostic confirmation by analytical toxicology{{cite|doi=10.1016/j.jemermed.2011.03.023|anchor=560c4a71}}{{flag|additional-citations-needed}}. A fatal case of [[substance:scopolamine]] [[glossary:intoxication]] — an inmate who smoked scopolamine tablets (buscopan) recreationally — demonstrated [[glossary:fatality|lethality]] at peripheral [[glossary:plasma-concentration|blood concentrations]] of 14 ng/mL. Pathology revealed cerebral and pulmonary edema{{cite|doi=10.1007/s00414-021-02583-2|anchor=2647738e}}{{flag|additional-citations-needed}}. While not a ''Mandragora'' preparation, this case establishes that scopolamine at toxic concentrations is directly lethal, with relevance to ''M. autumnalis'' preparations containing this alkaloid. ====Contaminant and adulterant risk==== ''Mandragora'' is wild-harvested with no standardized commercial preparations, no FDA or EMA-approved products, and no quality standards for herbal supplements. Key contamination and safety vectors include: * '''Misidentification as food plants:''' Documented cause of clinical poisoning — berries and leaves mistaken for borage, spinach, or other leafy vegetables{{cite|doi=10.1186/1757-1626-2-9331|anchor=28fb97d3}} * '''Commercial mislabeling:''' North American products sold as "mandrake" may contain ''Podophyllum peltatum'' (podophyllotoxin, a cytotoxic lignan) instead of ''Mandragora officinarum''{{cite|pubmed=9308513|anchor=d532a4ff}}. The two plants have radically different toxicological profiles and require different clinical management. * '''Batch variability:''' Alkaloid concentrations vary by species, plant part, developmental stage, and growing conditions. No standardization is possible from wild material. * '''Absence of testing infrastructure:''' No ISO/IEC-accredited laboratory testing programs, Certificate of Analysis requirements, or regulated supply chain exist for ''Mandragora'' preparations. No published data exist on heavy metal, pesticide, or mycotoxin contamination profiles in wild-harvested material{{flag|citation-needed}}. ===Psychological risks=== The [[substance_class:psychoactive/deliriant]] syndrome produced by anticholinergic toxicity is characterized by global cognitive disorganization, agitated [[effect:confusion]], vivid hallucinations indistinguishable from reality, and complete or partial amnesia for the episode{{cite|doi=10.1021/acschemneuro.8b00615|anchor=62c9b30b}}{{flag|additional-citations-needed}}. Unlike [[glossary:serotonergic-psychedelics]], the hallucinations lack insight — the user cannot recognize the hallucinatory nature of the experience during the episode (reality testing is abolished). Severe psychological [[glossary:distress]] during anticholinergic [[effect:delirium]] is the norm rather than the exception. The experiential character is consistently described as frightening, confusing, and dysphoric{{cite|doi=10.1371/journal.pone.0247688|anchor=23d82f0b}}{{flag|additional-citations-needed}}. No dose titration strategy has been established that reliably produces perceptible psychoactive effects without risk of severe toxicity. Persistent psychological sequelae from a single acute anticholinergic intoxication have not been systematically studied. Chronic anticholinergic exposure is associated with cognitive decline and increased dementia risk in pharmacoepidemiological studies of pharmaceutical anticholinergics, though this literature applies to sustained therapeutic dosing rather than acute plant intoxication{{flag|citation-needed}}. ===Tolerance and dependence=== No published data on [[glossary:tolerance]] development, physical dependence, or [[glossary:withdrawal]] exist specifically for ''Mandragora'' preparations. Tolerance to anticholinergic effects is recognized with repeated pharmaceutical scopolamine and atropine administration. No physical dependence syndrome or characterized withdrawal has been documented for anticholinergic agents as a class. Compulsive use of ''Mandragora'' or related anticholinergic Solanaceae is unlikely. Contemporary recreational use is extremely rare, and a survey of [[substance_class:psychoactive/hallucinogen]] users in Slovenia found that knowledge of anticholinergic Solanaceae had been largely lost — attributed to the severe toxicity and characteristically unpleasant nature of the experience{{cite|doi=10.1371/journal.pone.0247688|anchor=9592a92c}}{{flag|additional-citations-needed}}. ===Drug interactions=== Herb-[[glossary:drug-interaction]] data specific to ''Mandragora'' plant preparations do not exist. The following interactions are derived from pharmacological principles and pharmaceutical studies of the isolated alkaloids. '''CYP3A4 inhibitors:''' Grapefruit juice increases scopolamine AUC to approximately 142% of control and significantly prolongs Tmax, via [[glossary:inhibition]] of CYP3A-mediated intestinal [[glossary:metabolism]]{{cite|pubmed=16175141|anchor=2ec0bcb7}}{{flag|additional-citations-needed}}. Other [[glossary:cyp3a4]] [[glossary:inhibitor|inhibitors]] (ketoconazole, clarithromycin, ritonavir) would be expected to produce analogous effects on scopolamine-containing preparations. This interaction has mechanistic pharmacokinetic evidence but has not been studied with ''Mandragora'' preparations specifically. '''Additive anticholinergic burden:''' Co-administration with other anticholinergic agents — including first-generation antihistamines ([[substance:diphenhydramine]], chlorpheniramine), tricyclic [[substance_class:psychoactive/antidepressant|antidepressants]] (amitriptyline, nortriptyline), [[substance_class:psychoactive/antipsychotic|antipsychotics]] (chlorpromazine, olanzapine), and urological agents (oxybutynin, tolterodine) — carries risk of synergistic anticholinergic toxicity. This is a well-established pharmacodynamic interaction class. '''CNS depressants:''' Additive [[glossary:central-nervous-system|CNS]] [[effect:depression]] with [[substance:alcohol]], [[substance_class:psychoactive/opioid|opioids]], and [[substance_class:chemical/benzodiazepine|benzodiazepines]]. Co-ingestion of [[glossary:cns-depressants]] was noted in a fatal scopolamine case{{cite|doi=10.1007/s00414-021-02583-2|anchor=1a66a76b}}{{flag|additional-citations-needed}}. '''Cholinesterase inhibitors:''' Direct pharmacodynamic [[glossary:antagonism]] with donepezil, rivastigmine, and [[substance:galantamine]] — reduces [[glossary:efficacy]] of both the cholinesterase inhibitor and the anticholinergic. Clinically significant in dementia patients, where inadvertent anticholinergic exposure from herbal products can undermine therapeutic benefit. '''MAO inhibitors:''' A potential interaction based on shared CNS pathways has been proposed. No specific clinical case reports or mechanistic studies exist for ''Mandragora'' preparations with MAOIs{{flag|citation-needed}}. ===Contraindications=== '''Cardiac disease:''' Supraventricular tachycardia with pulse rates exceeding 170 bpm has been documented in ''Mandragora'' poisoning{{cite|doi=10.1186/1757-1626-2-9331|anchor=b255b5e1}}{{flag|additional-citations-needed}}. Any pre-existing [[glossary:arrhythmia|cardiac arrhythmia]], coronary artery disease, or heart failure constitutes an absolute [[glossary:contraindication]] to intentional use. '''Elderly individuals:''' Enhanced anticholinergic [[glossary:sensitivity]] in older adults is well established. A case of severe scopolamine toxicity via transdermal patch was documented in a 66-year-old patient{{cite|doi=10.1093/milmed/usz086|anchor=e01057ed}}{{flag|additional-citations-needed}}. '''Pregnancy:''' Scopolamine crosses the placenta{{cite|pubmed=16175141|anchor=c57da5c3}}{{flag|additional-citations-needed}}. While pharmaceutical scopolamine is considered non-teratogenic, the uncontrolled alkaloid exposure from plant preparations and the risk of maternal anticholinergic toxidrome constitute a contraindication. '''Concurrent anticholinergic medications:''' Patients taking any [[glossary:medication]] with anticholinergic properties face risk of additive toxicity. '''Concurrent cholinesterase inhibitor therapy:''' Direct pharmacodynamic antagonism creates a dual-harm scenario — reduced therapeutic efficacy of the cholinesterase inhibitor and risk of anticholinergic breakthrough. '''Hepatic impairment:''' Scopolamine undergoes extensive hepatic CYP3A4 metabolism{{cite|pubmed=16175141|anchor=f8400b3e}}{{flag|additional-citations-needed}}. Impaired hepatic function would be expected to increase systemic exposure and prolong effect duration. '''Pediatric populations:''' Children are particularly vulnerable to anticholinergic toxidrome; severe reactions at lower doses are documented for pharmaceutical anticholinergics{{flag|safety-citation-needed}}. '''Glaucoma:''' Anticholinergic mydriasis can precipitate acute angle-closure glaucoma in susceptible individuals{{flag|citation-needed}}. '''Urinary obstruction:''' Anticholinergic-induced urinary retention can exacerbate prostatic hypertrophy or other obstructive uropathy{{flag|citation-needed}}.

''Mandragora'' spp. are [[glossary:unscheduled|not scheduled]] under any of the three major UN [[glossary:drug-control|drug control conventions]]: the 1961 Single Convention on Narcotic Drugs, the 1971 [[glossary:convention-on-psychotropic-substances]], or the 1988 Convention Against Illicit Traffic. The principal alkaloids hyoscyamine and [[substance:scopolamine]] are also not scheduled internationally, though both are controlled as prescription-only pharmaceutical agents in most jurisdictions when manufactured as medicines. Atropine and scopolamine appear on the WHO List of Essential Medicines as legitimate pharmaceuticals{{cite|doi=10.1007/s13659-022-00357-w|anchor=78c25dac}}.

Jurisdiction	Classification	Key provisions
United States (federal)	Uncontrolled	''Mandragora officinarum'' and its extracts are not scheduled under the Controlled Substances Act. The plant is legal to possess, cultivate, buy, and distribute without a federal license. Supplement sales must conform to DSHEA{{cite|name=erowid-mandrake-law|type=book|author=Erowid|year=2024|title=Erowid Mandrake (Mandragora officinarum) Law Vault|anchor=2f96938e}}.
Louisiana (US state)	Prohibited for human consumption	Louisiana Act No. 159 (effective August 8, 2005) explicitly names ''Mandragora officinarum'' among 40 plants prohibited when intended for human consumption. Possession, cultivation, and harvesting for aesthetic, landscaping, or decorative purposes are exempt{{cite|name=erowid-mandrake-law|type=book|author=Erowid|year=2024|title=Erowid Mandrake (Mandragora officinarum) Law Vault|anchor=c3498c31}}.
Other US states	No specific bans identified	No other state-level prohibitions on ''Mandragora'' were identified in published literature{{flag|citation-needed}}.
United Kingdom	Prescription only (''M. autumnalis'' in medicines)	The Prescription Only Medicines (Human Use) Order 1997 identifies ''Mandragora autumnalis'' as a substance making medicinal products prescription-only. Whether this legislation extends to the taxonomically distinct ''M. officinarum'' is unclear{{cite|name=erowid-mandrake-law|type=book|author=Erowid|year=2024|title=Erowid Mandrake (Mandragora officinarum) Law Vault|anchor=299f3b66}}.
European Union	No EU-wide scheduling	The European Medicines Agency does not recognize any ''Mandragora'' species as an approved herbal medicinal product under the European Directive on Traditional Herbal Medicinal Products{{cite|name=erowid-mandrake-law|type=book|author=Erowid|year=2024|title=Erowid Mandrake (Mandragora officinarum) Law Vault|anchor=4a61d10a}}.
Germany	No specific data found	No regulatory data specific to ''Mandragora'' were identified{{flag|citation-needed}}.
Australia	No specific data found	No regulatory data specific to ''Mandragora'' were identified{{flag|citation-needed}}.
Israel	No specific data found	No regulatory data specific to ''Mandragora'' were identified{{flag|citation-needed}}.

===Detection=== Standard immunoassay drug panels do not detect hyoscyamine or scopolamine. Forensic or clinical confirmation requires specific LC-MS/MS methodology{{cite|doi=10.1016/j.jpba.2019.112945|anchor=143f2026}}{{cite|pubmed=31573667|anchor=8af5b9cb}}. Anticholinergic syndrome is typically diagnosed clinically by symptom pattern rather than by toxicological screening.